establish better foundat propel turnaround expect
compani make stride believ narr larg focu
execut sequenti improv new product includ rosa
knee applic launch remain sidelin gain increas
confid top-lin acceler potenti
continu make progress turnaround
make solid progress suppli recoveri qualiti remedi well tee
import new product introduct investor optim toward acceler
organ revenu back weight averag market growth rate wamgr
ration improv view top-lin margin bottom-lin guidanc realist
anticip next month serv anoth build year better
posit recaptur share total joint spine ortho segment
expect faster expect recov primarili due manag clear messag
expect return share gain knee hip kick although
path back de-risk zbh revenu base
domin knee hip total market deceler
drive zbh wamgr closer market dont experi rebound
increasingli optimist zbh prospect becom construct
gain convict path organ revenu growth north
understand margin expans potenti beyond
face easiest organ revenu growth comparison declin
constant bill day constant currenc basi howev face partial
sell day assign bone cement fx headwind forecast
organ constant bill day constant currenc revenu growth repres
sequenti deceler comp adjust basi management guid om low end
rang impli contract forecast ep vs
street estim repres declin see risk estim
manag continu stellar job manag expect keep street
number reason rang believ aao unveil rosa robot total
knee spine applic serv bigger earli catalyst result
maintain market perform increas price
increas price target account increas
optim top-lin acceler potenti well recent expans
larg cap median multipl valuat analysi consist earn
ebitda multipl repres approxim two turn discount
peer group view discount multipl assign appropri given
lower top-lin growth profil stunt margin stori look becom
construct pend visibl revenu acceler driver improv
execut remain sidelin market perform rate
pleas see page report import disclosur
market perform rate stem zbh outsiz exposur reconstruct joint
market make compani heavili reliant hip knee implant year
weak recon market cap sale growth biomet merger continu
roll-out persona knee system better-posit captur market share
strengthen recon busi howev recent suppli issu delay zbh return
market growth rate remedi suppli constraint demonstr sustain
improv recon well compani non-recon area key
remedi manufactur issu
led recent fda
elimin exist suppli constraint
resolut suppli constraint line
manag guidanc
faster-than-expect resolut
continu success integr
continu stabil global
merger acquisit synergi
anticip
deterior global recon market
market share loss knee hip
design sell reconstruct spinal trauma devic compani also
biolog sport medicin dental bone heal microfix relat surgic devic
product portfolio manag oper three geograph segment
america consist unit state includ north central
south american market europ consist europ includ middl east
africa market asia pacif compris japan australia select market
zimmer merg biomet june greatli expand orthoped scale
believ guidanc repres appropri conserv outlook
zbh guidanc contempl sale growth cc ep
basi point headwind foreign exchang believ top-lin guidanc strike
appropri next level revenu growth perform constant
currenc growth experienc weight averag market growth rate
manag expect meet exceed manag foremost prioriti remain
acceler revenu growth requir increas level invest
next sever quarter although zbh exist pipelin capabl achiev in-lin
market growth manag state above-market growth requir aggress
portfolio manag diversifi busi migrat portfolio toward
accomplish includ improv suppli new product
introduct togeth reinvigor sale forc traction enhanc surgeon
relationship intend transit beyond focu product suppli
part resolv upcom quarter manag hone overal
suppli chain effici regain full trust commerci organ well
deliv cadenc new product launch recent launch persona partial knee
persona tm tibia produc favor result tm tibia exceed
case limit launch upcom launch persona revis system
rosa robot progress in-lin expect rosa slightli ahead although
lack suppli expect barrier target manag note
still take time fulli restor salesforc confid inventori
allow go fulli offens expect full product portfolio includ
key pipelin product like rosa second half point salesforc
offens
forecast revenu repres organ constant bill day
constant currenc growth repres acceler despit headwind
includ disrupt relat termin distribut agreement
zbh bone cement supplier dynam expect impact
per quarter headwind expect persist
anniversari unless fulli transit custom intern produc bone
cement unlik scenario see note detail
forecast organ constant bill day constant currenc growth
compar softest year detail forecast per busi
knee hip year primari focu suppli recoveri saw
knee franchis struggl growth perspect busi unit deliv
constant currenc growth ww experienc growth declin constant
currenc despit growth challeng abl make steadi
improv throughout year deliv goal allevi pressur
suppli constraint indic earn call longer consid
suppli barrier forward progress term top-lin perform
face weak comp abl deliv knee sale
result line consensu estim time also mark signific
mileston product portfolio standpoint fda grant clearanc rosa
robot system total knee replac develop well posit updat
provid persona system like aid bring attent investor toward
posit futur outlook divis rather focus well understood
challeng pose suppli constraint burden busi past
hip franchis experi declin growth quit sever knee howev
group immun troubl relat suppli constraint slow start
hip sale rebound stellar print constant currenc growth
follow growth figur nearli constant currenc made clear
result partli due weak comp expect
norm move forward
although challeng year knee sever prospect
horizon could serv catalyst franchis look go offens
spend much last two year recoveri aforement fda approv
rosa like result full launch robot system late leav
posit nice deliv revenu growth goal complement
launch rosa see rosa analysi also benefit addit
offer persona knee system persona revis event slate
round exist persona option recent releas persona
partial knee persona cementless hip franchis cast spotlight
recent quarter given excit surround upcom launch knee
worth note anticip busi unit follow similar growth trajectori
knee franchis stagnant growth neighborhood expect first
half potenti expand back half year
compani fulli recov suppli constraint
look knee franchis face weakest comp
time last year compani still midst recov suppli chain
report constant currenc growth quarter set low bar
franchis overcom anticip fulli offens
forecast constant currenc growth knee first quarter expect
low growth figur also case wait full launch
sever product kick jumpstart return growth back half
hip franchis also face weakest comp year
conserv forecast repres sequenti decel
 forecast constant currenc growth busi mark
slight acceler growth rate post expect slight
acceler back half year growth final two quarter
year compar growth first two quarter busi
featur mani high-growth legaci biomet product especi hard hit suppli
issu north campu suppli north campu began return first quarter
acceler balanc year creat favor
setup busi first half
first quarter project constant currenc growth easiest
comp year growth rate state earlier benefit time
suppli remedi effort north campu
spine/cmf/thorac spine model growth would
acceler flat level growth experienc decis
make chang within senior leadership spine allow channel strategi
time develop appear pay strung togeth three consecut
quarter posit growth transit howev
result oper disrupt last year includ first quarter thu spine
 cmf benefit softest comp year forecast growth
dental expect dental growth improv
growth rate given histor weak franchis result
restructur competit market dynam dental one zbh weaker
busi sever quarter would impli continu market share eros
near term restructur sale forc key market yet yield
meaning sale benefit manag previous state busi begin
stabil focus return franchis posit growth despit
comp second easiest year model assum constant
currenc growth rate first quarter
although signific om expans unlik top-lin stabil re-rout
guidanc beyond top line expect adjust effect tax rate
rang roughli line rate seen
throughout ep guidanc impli nearli growth
top end rang full-year free cash flow expect rang billion-
billion includ one-tim payment relat patent litig
oper margin expect repres bp contract
midpoint
gross margin estim repres yoy declin much higher
spend product today continu capit inventori therefor
elev cost implement dual-sourc strategi instal
effici manufactur qualiti control process fulli reflect
inventori fulli turn anticip forecast
sale repres increas previou year continu invest
new product robot expect flat sg spend build
special sale forc moder begin leverag commerci
infrastructur believ could upsid margin specif sg
achiev strong oper leverag rep return offens although
factor equat yoy margin contract believ om hit floor
improv thereaft remain optimist zbh multi-year margin
expans potenti stem initi around manufactur effici soften
suppli headwind sku ration top-lin leverag believ guidanc
set conserv allow room maneuv ultim priorit
effort first drive top-lin growth even requir ad spend ultim view
upsid ep guidanc deriv better expect top-lin growth
forecast oper margin compress low
ep part margin compress relat estim
decreas report revenu impact sever fx headwind
year dial current rate one day bill day headwind first
half alloc half first quarter result
headwind assumpt model
compani report thomson eikon cowen compani
mm except oper biomet oper cowen
compani report cowen compani
mm except ex-fx ex-fx ex-fx ex-fx ex-fx ex-fx ex-fx ex-fx ex-fx spine ex-fx ex-fx ex-fx ex-fx revenu less growth impact ex-fx growth day day impact report ex-fx ex-fx ex sell day cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
orthoped industri risk continu util pressur account
organ play bigger role health care deliveri competit dynam global
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken consum demand develop market
econom and/or polit uncertainti emerg market intellectu properti
deeper util pressur recon busi us europ worsen
competit dynam global potenti regulatori delay reject failur
devic clinic trial econom sensit price pressur and/or weaken
demand develop market econom and/or polit uncertainti emerg
market fluctuat foreign exchang rate
